Related Experiment Video
Updated: Jul 18, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Synopsis of a roundtable on validating novel therapeutics for multiple myeloma
William Dalton1, Kenneth C Anderson
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Purpose:
With the identification of new molecular targets and pathways, many new therapeutic approaches are being identified for potential application in the treatment of multiple myeloma. New chemical compounds and biologics have been developed against molecular targets with substantial scientific evidence that these targets are involved in myeloma development, progression, or relapse. To safely and rapidly bring these advances to bear on the disease, new preclinical models in cells and animals need to be established, as well as prioritization and standardization in current preclinical and clinical validation. An experts' roundtable was convened in November 2005 to discuss shortcomings in current preclinical models and discuss what models are needed to best validate therapeutics and combinations of therapies for multiple myeloma.
Conclusions:
This exciting event brought together experts in compound validation, preclinical development, and experts in multiple myeloma from academic institutions and the pharmaceutical and biotechnology industries. The goals were to evaluate an algorithm for therapeutic validation and discuss in vitro modeling for target discovery, animal models for preclinical development, and models for testing drug combinations.
Insights
Experts convened to address the need for improved preclinical models in multiple myeloma research. This aims to accelerate the validation of novel therapeutics and combination therapies for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment is advancing with new molecular targets and therapeutic strategies.
- Developing novel chemical compounds and biologics requires robust validation methods.
Purpose of the Study:
- To identify shortcomings in current preclinical models for multiple myeloma.
- To establish and standardize new preclinical models for validating therapeutics and combination therapies.
- To accelerate the clinical translation of novel multiple myeloma treatments.
Main Methods:
- Convened an experts' roundtable in November 2005.
- Discussed in vitro modeling for target discovery.
- Evaluated animal models for preclinical drug development and combination therapy testing.
Main Results:
- Identified critical needs for improved preclinical models in multiple myeloma.
- Proposed an algorithm for therapeutic validation.
- Highlighted the importance of standardized models for drug development.
Conclusions:
- Enhanced preclinical models are essential for validating novel therapeutics and combination therapies in multiple myeloma.
- Collaboration between academia and industry is crucial for advancing multiple myeloma treatment.
- Standardized validation processes will expedite the delivery of effective treatments to patients.
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy